Phase II Study: Revlimid successful

Oct 12, 2006

U.S. scientists say a Phase II trial of Revlimid in patients with incurable blood cancer has produced positive results.

The researchers at the Moffitt Cancer Center and Research Institute in Tampa., Fla., say the study found more than 75 percent of patients reduced their need for transfusions and two-thirds were completely freed from the need for transfusions.

Most significantly, in 45 percent of patients, there was no detectable trace of the cancer. After two years of follow-up, patients continue to respond and do well on treatment, representing a breakthrough in treatment for myelodysplastic syndrome, or MDS.

"These new, landmark data demonstrate that Revlimid in some cases, eliminates all signs of the cancer's genetic cause -- an abnormality on the chromosome 5 -- can reduce or even eliminate the need for transfusions in many patients with MDS, and after two years these responses have continued to hold," said Dr. Alan List, professor of oncology and medicine, the lead author of the study.

MDS, a cancer in which the bone marrow fails to make enough functioning blood cells, kills up to 70,000 people annually.

The research appears in the Oct. 5 issue of the New England Journal of Medicine.

Copyright 2006 by United Press International

Explore further: Team finds new genetic anomalies in lung cancer

add to favorites email to friend print save as pdf

Related Stories

Cancer wins may be bigger than they seem

Jun 09, 2010

(AP) -- Doctors reported gains against nearly every form of cancer at a conference that ended this week. Yet when Will Thomas heard about an advance against prostate cancer, he wanted to know just one thing: "Is it a cure?"

Recommended for you

Suppressing a protein reduces cancer spread in mice

6 hours ago

Scientists have found that decreasing the levels of or blocking a specific protein commonly found in humans and many other animals allowed them to slow the spread of two different kinds of cancer to the lungs ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.